[Stiff Person Syndrome (SPS)](/diseases/stiff-person-syndrome) is a rare [autoimmune neurological disorder](/mechanisms/autoimmune-encephalitis) characterized by progressive muscle stiffness and painful spasms, primarily affecting the trunk and proximal limb muscles [1]. The disease results from autoantibody-mediated impairment of [GABAergic](/mechanisms/gabaergic-dysfunction) (gamma-aminobutyric acid) inhibitory neurotransmission, leading to continuous motor neuron activation and sustained muscle contraction [2]. SPS is considered a rare disease but is increasingly recognized as having important associations with [paraneoplastic syndromes](/diseases/paraneoplastic-syndromes) and potential [neurodegenerative processes](/mechanisms/neurodegeneration). [@waliszewskaprosol2022]
The hallmark of SPS is axial and limb rigidity with superimposed painful muscle spasms that can be triggered by emotional stress, sensory stimuli, or voluntary movement. The disorder typically follows a progressive course, leading to significant disability and impaired quality of life. Importantly, SPS has been associated with various [autoimmune conditions](/mechanisms/autoimmune-encephalitis) and, in some cases, with underlying malignancies, suggesting a [paraneoplastic etiology](/diseases/paraneoplastic-syndromes). [@graus2007]
[Stiff Person Syndrome (SPS)](/diseases/stiff-person-syndrome) is a rare [autoimmune neurological disorder](/mechanisms/autoimmune-encephalitis) characterized by progressive muscle stiffness and painful spasms, primarily affecting the trunk and proximal limb muscles [1]. The disease results from autoantibody-mediated impairment of [GABAergic](/mechanisms/gabaergic-dysfunction) (gamma-aminobutyric acid) inhibitory neurotransmission, leading to continuous motor neuron activation and sustained muscle contraction [2]. SPS is considered a rare disease but is increasingly recognized as having important associations with [paraneoplastic syndromes](/diseases/paraneoplastic-syndromes) and potential [neurodegenerative processes](/mechanisms/neurodegeneration). [@waliszewskaprosol2022]
The hallmark of SPS is axial and limb rigidity with superimposed painful muscle spasms that can be triggered by emotional stress, sensory stimuli, or voluntary movement. The disorder typically follows a progressive course, leading to significant disability and impaired quality of life. Importantly, SPS has been associated with various [autoimmune conditions](/mechanisms/autoimmune-encephalitis) and, in some cases, with underlying malignancies, suggesting a [paraneoplastic etiology](/diseases/paraneoplastic-syndromes). [@graus2007]
The disease predominantly affects adults, with a female predominance of approximately 2:1 [5]. Onset typically occurs in the fourth to sixth decade of life, although childhood and late-onset cases have been reported [6]. The prevalence of SPS is estimated at 1-2 per million population, making it one of the rarest neurological disorders [7]. [@solimena1990]
SPS shows a clear female predominance, with women accounting for 60-70% of cases in most series [8]. The peak age of onset is between 30 and 60 years, with a median age of approximately 45 years [9]. However, cases have been reported across the age spectrum, from early childhood to late adulthood. [@skorupka2020]
The disease is worldwide in distribution, with cases reported in all ethnic groups. However, population-based prevalence estimates are limited due to the rarity of the condition and frequent misdiagnosis as conversion disorder, tetanus, or other movement disorders [10]. [@de1993]
SPS is frequently associated with other [autoimmune conditions](/mechanisms/autoimmune-encephalitis) [11]: [@butler1993]
Approximately 5-10% of SPS cases are paraneoplastic, associated with underlying malignancies [12]: [@pittock2003]
The primary autoantibodies in SPS target [glutamic acid decarboxylase (GAD)](/proteins/gad-protein), the enzyme responsible for [GABA synthesis](/mechanisms/gabaergic-dysfunction) [13]: [@manto2020]
Anti-GAD65 Antibodies: Present in 60-80% of classic SPS cases [14]. These antibodies recognize the 65-kDa isoform of GAD, which is primarily localized to synaptic terminals in GABAergic neurons. Antibody titers typically correlate with disease severity and may persist despite immunotherapy. [@dinkel2003]
Anti-Amphiphysin Antibodies: Associated with paraneoplastic SPS, particularly in patients with [breast cancer](/diseases/breast-cancer-neurological) or [small cell lung cancer](/diseases/small-cell-lung-cancer-neurological) [15]. Amphiphysin is a synaptic protein involved in [synaptic vesicle recycling](/mechanisms/synaptic-vesicle-recycling). [@raha2021]
Anti-Gephyrin Antibodies: Rare but described in SPS patients [16]. Gephyrin is a postsynaptic scaffolding protein critical for GABA_A and glycine receptor clustering. [@ishida2020]
Anti-Ri Antibodies: Paraneoplastic antibodies associated with SPS in some cancer patients [17]. [@zhang2022]
The autoantibodies in SPS impair GABAergic neurotransmission through multiple mechanisms [18]: [@martinezrodriguez2020]
Enzymatic Inhibition: Anti-GAD antibodies directly inhibit GAD enzymatic activity, reducing [GABA synthesis](/mechanisms/gabaergic-dysfunction) [19]. This leads to decreased GABA release from presynaptic terminals. [@lorusso2018]
Synaptic Dysfunction: Antibodies may interfere with synaptic vesicle trafficking and release of GABA [20]. Impaired vesicle cycling reduces quantal GABA release. [@meinck2001]
Receptor Alteration: Some antibodies may affect postsynaptic [GABA_A receptor](/proteins/gabaa-receptor) function or localization [21]. This compounds the presynaptic deficit. [@barker2013]
Complement-Mediated Injury: Evidence suggests [complement activation](/mechanisms/complement-system-pathway) may contribute to synaptic loss in severe cases [22]. [@fook2019]
Neuroimaging studies in SPS reveal characteristic abnormalities [23]: [@karkar2021]
Muscle Stiffness: Progressive, axial-predominant muscle stiffness is the defining feature of SPS [24]. Stiffness typically begins in the trunk (paraspinal and abdominal muscles) and spreads proximally to involve the limbs. The stiffness is often worse in the morning and improves slightly with movement. [@guimaraes2020]
Muscle Spasms: Painful, violent muscle spasms occur spontaneously or are triggered by [25]: [@sarva2016]
The pattern of muscle involvement in SPS includes [26]: [@vincent2011]
Axial Muscles (universally affected): [@ropper2023]
Autonomic Dysfunction: Some patients develop autonomic abnormalities including hypertension, tachycardia, and hyperhidrosis during spasms [27]. [@pagano2021]
Eye Movement Abnormalities: OcularMotor involvement is uncommon but has been reported [28]. [@cross2019]
Cognitive Function: Cognitive abilities are generally preserved, but anxiety and depression are common [29]. [@murinson2004]
SPS typically follows a progressive course over months to years [30]: [@miller2020]
The diagnosis of SPS is primarily clinical, based on established criteria [31]: [@penn2012]
Core Criteria: [@dalakas2001]
Supportive Criteria: [@bcells2018]
Serum Testing [32]: [@vernino2003]
EMG findings in SPS are characteristic but not specific [34]: [@tansley2017]
Brain and spine [MRI](/diagnostics/mri-neurodegeneration) are typically normal in SPS but are essential to exclude structural causes [35]. In some cases, [MRI](/diagnostics/mri-neurodegeneration) may show: [@khosousi2019]
SPS must be distinguished from other causes of muscle stiffness and spasms [37]: [@pham2021]
| Condition | Key Distinguishing Features | [@de2023]
|-----------|----------------------------| [@hattan2018]
| Tetanus | Trismus, autonomic dysfunction, history of wound | [@blum2009]
| Neuromyotonia | Myokymia on EMG, KV channel antibodies | [@sechi2016]
| Isaacs Syndrome | Continuous muscle fiber activity, hyperhidrosis | [@darnell2018]
| Conversion Disorder | Inconsistent examination, psychiatric features | [@elabassi2021]
| Ankylosing Spondylitis | Structural vertebral changes, HLA-B27 | [@henson2020]
| ERP Syndrome | Myoclonus predominant, different triggers | [@green2018]
| Progressive Encephalomyelitis with Rigidity | Brainstem signs, rapid progression | [@solimena2018]
Immunotherapy is the cornerstone of SPS treatment, aiming to reduce antibody-mediated neuronal dysfunction [38]: [@kashida2017]
First-Line Therapies: [@manto2017]
Muscle Relaxants [50]: [@dalmau2020]
In paraneoplastic SPS, treatment of the underlying malignancy is essential [53]:
SPS is typically a chronic, progressive condition, but appropriate treatment can significantly improve quality of life [54]:
Mortality in SPS is primarily related to [55]:
Quality of life is significantly impaired in untreated SPS but improves substantially with multimodal therapy [56]. Key domains affected include:
Animal models of SPS have provided insights into disease mechanisms [57]:
GAD Knockout Mice: Partial GAD deficiency leads to anxiety-like behavior and increased seizure susceptibility, but does not fully replicate SPS [58].
Passive Transfer Models: Transfer of anti-GAD antibodies into mice produces some neurochemical abnormalities but not full SPS phenotype [59].
Active Immunization Models: Immunization with GAD protein produces autoantibodies and some behavioral changes [60].
Current research areas in SPS include [61]:
SPS is part of a spectrum of autoimmune encephalopathies targeting synaptic antigens [62]:
| Disorder | Target Antigen | Key Features |
|----------|---------------|--------------|
| SPS | GAD65, Amphiphysin | Stiffness, spasms |
| PERM | Glycine receptor | Stiffness, brainstem signs |
| Encephalitis PEX | LGI1 | Limbic encephalitis, seizures |
| Morvan Syndrome | CASPR2 | Peripheral nerve hyperexcitability |
SPS is caused by autoantibodies against GAD, the rate-limiting enzyme for [GABA synthesis](/mechanisms/gabaergic-dysfunction) [4](/https:/pubmed.ncbi.nlm.nih.gov/25939008/):
GAD isoforms:
The loss of GABAergic inhibition leads to:
Approximately 5-10% of SPS cases are paraneoplastic:
Diagnosis is based on:
Serum:
-- An- Thyroid ant- Type 1 diabet
CSF:
First-line treatments:
SPS shares features with cerebellar degeneration:
With appropriate treatment: